Leadership rejig aligns with biologics integration and wider organisational overhaul
Diavorin and Vobexoryn mark Biocon’s first own-brand GLP-1 rollout in Europe
The QIP drew major domestic and global investors as Biocon prepares to strengthen its balance sheet
